TLSA (Tiziana Life Sciences) Short Percentage of Float


TLSA Tiziana Life Sciences Ltd TLSA
30 GF Score
Price $1.13
! 2 Warning Signs
View Full Analysis

What is Tiziana Life Sciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TLSA vs DTIL, MIST, EQ: Short Percentage of Float Comparison

For the Biotechnology subindustry, Tiziana Life Sciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tiziana Life Sciences Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tiziana Life Sciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Tiziana Life Sciences's Short Percentage of Float falls into.


TLSA
30GF Score
Tiziana Life Sciences Ltd TLSA
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tiziana Life Sciences Business Description

Other Exchanges 0RP:Germany
Address 2 Church Street, Clarendon House, Hamilton, BMU, HM 11
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
30GF Score

Get the complete analysis for TLSA

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.13
Price